SOLICITATION NOTICE
B -- Pathotyping of Highly Pathogenic Avian Influenza Virus and Reassortant Vaccine Candidate Virus in White Leghorn Chickens
- Notice Date
- 6/12/2007
- Notice Type
- Solicitation Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, Center for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, GA, 30341-4146, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- 2007-Q-09637
- Response Due
- 6/19/2007
- Archive Date
- 7/6/2007
- Description
- The Centers for Disease Control and Prevention (CDC), Coordinating Center for Infectious Diseases (CCID), National Center for Infectious & Repsiratory Diseases (NCIRD), Influenza Division (ID) will create reassortant viruses from Highly Pathogenic Avian Influenza (HPAI) wild type viruses as vaccine candidates. The CDC has a requirement for a study titled, Pathotyping of HPAI Virus A/Anhui/01/05 (H5N1) and Reassortant Vaccine Candidate A/Anhui01/2005(H5N1)-PR8-IBCDC-RG6 Virus in White Leghorn Chickens, to evaluate the pathogenicity of the reassortant avian influenza virus candidate versus the HPAI wild type virus by intravenous and intranasal pathotyping procedures to ensure that they have been rendered non-pathogenic. The intravenous and intranasal pathotyping procedures are prescribed by CDC for this evaluation. To qualify for this requirment a bidder must have the following capabilties relative to conducting research into the safety and performance of avian influenza technologies: a USDA approved Biosafety Level 3 or BSL3-Enhanced laboratory for working with HPAI; USDA and APHIS Select Agent Approvals for HPAI (facilites and individuals) and to perform Biological Testing Using Animals; experience in receipt and transport of influenza strains; IBC experience in AIV/HPAI protocol review; internal R&D vaccine studies using recombinant HA protein; AIV assay development; AIV reagent production; AIV molecular assays (RT-PCR). Performance of this study should begin no later than 22 June 2007. Based on the mandatory capabilities listed above and the government?s requirement for immediate performance, the CDC plans to award a noncompetitive contract action to Benchmark Biolabs, Inc; if, however, you believe you possess all of the mandatory capabilites and can meet the immediate start schedule, you may submit a bid, proposal, or quotation to the Contract Specialist no later than 19 June 2007 which will be considered by the CDC. To obtain an electronic copy of the SOW/CDC Protocol, request by email to bskennedy@cdc.gov.
- Record
- SN01316314-W 20070614/070612220400 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |